

April 18, 2020

Listing Department  
**BSE Limited**  
P J Towers, Dalal Street, Fort,  
Mumbai – 400001

**Code: 532321**

Listing Department  
**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (E),  
Mumbai – 400051

**Code: CADILAHC**

Re.: Press Release

Dear Sir / Madam,

Please find enclosed a Press Release dated April 18, 2020 titled “Zydus receives final approval from the USFDA for Baclofen Tablets”.

The contents of the Press Release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and investors’ at large.

Thanking you,

Yours faithfully,  
For, **CADILA HEALTHCARE LIMITED**

**DHAVAL N. SONI**  
**COMPANY SECRETARY**

**Encl.:** As above

## Zy+us receives final approval from USFDA for Baclofen Tablets

---

*Ahmedabad, April 18, 2020*

Zy+us Cadila has received final approval from the USFDA to market Baclofen Tablets, 5 mg.

Baclofen is used to treat muscle spasms caused by certain conditions such as multiple sclerosis, spinal cord injury/disease. It works by helping to relax the muscles. It will be manufactured at the group's formulations manufacturing facility at Baddi.

The group now has 288 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.

### **About Zy+us Cadila**

Zy+us Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally. Zy+us aspires to be a research-based pharmaceutical company by 2020.

\*\*\*